PMID- 31190983
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 11
DP  - 2019
TI  - The safety and serious adverse events of approved ALK inhibitors in malignancies: 
      a meta-analysis.
PG  - 4109-4118
LID - 10.2147/CMAR.S190098 [doi]
AB  - Background: A total of 2%-7% of non-small cell lung cancer (NSCLC) patients have 
      anaplastic lymphoma kinase (ALK) mutations. At present, three or more generations 
      of ALK inhibitors have been used for ALK-positive NSCLC treatment, including 
      crizotinib, alectinib, ceritinib, and brigatinib. Although most adverse events 
      (AEs) of ALK inhibitors are grades 1 to 2 and generally can be well tolerated, 
      serious adverse events (SAEs) of ALK inhibitors lack data analysis, and the lung 
      toxicity of ALK inhibitors needs attention. Thus, we performed this meta-analysis 
      to evaluate the safety of ALK inhibitors, especially in terms of drug-related 
      SAEs. Methods: A total of 19 studies from 4 databases (PubMed, Science Direct, 
      ClinicalTrials.gov and Cochrane Library) were included in this meta-analysis. All 
      statistical analyses in this meta-analysis were performed with the STATA 14.0 
      software. We analyzed the incidences of total AEs, total SAEs and SAEs for 
      different ALK inhibitors. Results: AEs of the ALK inhibitors occurred in almost 
      all participants, and SAEs occurred in more than 20% of the participants. For 
      ceritinib and brigatinib, SAEs occurred in more than 40% of the participants. 
      Alectinib is most likely the safest of the two generations of ALK inhibitors. 
      Generally, the ALK inhibitors showed significant lung toxicity. Conclusion: In 
      conclusion, attention should be focused on ALK inhibitor-related SAEs, especially 
      lung toxicity. According to this meta-analysis, alxectinib seems to be the safest 
      ALK inhibitor. Physicians should focus on the related SAEs when prescribing ALK 
      inhibitors.
FAU - Hou, Helei
AU  - Hou H
AD  - Department of Medical Oncology, The Affiliated Hospital of Qingdao University, 
      Qingdao University, Qingdao, People's Republic of China.
FAU - Sun, Dantong
AU  - Sun D
AD  - Department of Medical Oncology, The Affiliated Hospital of Qingdao University, 
      Qingdao University, Qingdao, People's Republic of China.
FAU - Liu, Kewei
AU  - Liu K
AD  - Department of Medical Oncology, The Affiliated Hospital of Qingdao University, 
      Qingdao University, Qingdao, People's Republic of China.
FAU - Jiang, Man
AU  - Jiang M
AD  - Department of Medical Oncology, The Affiliated Hospital of Qingdao University, 
      Qingdao University, Qingdao, People's Republic of China.
FAU - Liu, Dong
AU  - Liu D
AD  - Department of Medical Oncology, The Affiliated Hospital of Qingdao University, 
      Qingdao University, Qingdao, People's Republic of China.
FAU - Zhu, Jingjuan
AU  - Zhu J
AD  - Department of Medical Oncology, The Affiliated Hospital of Qingdao University, 
      Qingdao University, Qingdao, People's Republic of China.
FAU - Zhou, Na
AU  - Zhou N
AD  - Department of Medical Oncology, The Affiliated Hospital of Qingdao University, 
      Qingdao University, Qingdao, People's Republic of China.
FAU - Cong, Jing
AU  - Cong J
AD  - Department of Medical Oncology, The Affiliated Hospital of Qingdao University, 
      Qingdao University, Qingdao, People's Republic of China.
FAU - Zhang, Xiaochun
AU  - Zhang X
AD  - Department of Medical Oncology, The Affiliated Hospital of Qingdao University, 
      Qingdao University, Qingdao, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20190507
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC6511621
OTO - NOTNLM
OT  - ALK inhibitors
OT  - lung toxicity
OT  - safety
OT  - serious adverse events
COIS- The authors report no conflicts of interest in this work.
EDAT- 2019/06/14 06:00
MHDA- 2019/06/14 06:01
PMCR- 2019/05/07
CRDT- 2019/06/14 06:00
PHST- 2018/10/08 00:00 [received]
PHST- 2019/03/12 00:00 [accepted]
PHST- 2019/06/14 06:00 [entrez]
PHST- 2019/06/14 06:00 [pubmed]
PHST- 2019/06/14 06:01 [medline]
PHST- 2019/05/07 00:00 [pmc-release]
AID - 190098 [pii]
AID - 10.2147/CMAR.S190098 [doi]
PST - epublish
SO  - Cancer Manag Res. 2019 May 7;11:4109-4118. doi: 10.2147/CMAR.S190098. eCollection 
      2019.